Observational analysis shows reduced work of breathing with a new NCPAP device in low birthweight newborns, suggesting lower chronic lung disease risk.
A new NCPAP device currently used in Europe has shown to be both efficacious in treating hyaline membrane disease (HMD) and to be connected with a low occurrence of chronic lung disease in low birthweight newborn infants. To determine if the intrinsic mechanical properties of the new device would reduce the newborns’ work of breathing, this study compares the simulated airway pressure and the imposed work profiles of the new device to those of a conventional nasal prong device used in the United States. The imposed work of the new NCPAP device was found to be approximately one-quarter that of the conventional device. The research data confirm that treatment with the new NCPAP device carries a potential clinical benefit for newborn infants with respiratory distress.
No takes yet. Share an insight, caveat, or question.
Amy Y. Lee (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: